P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis
Simon J. Harrison,Paul G. Richardson,Adrian Alegre,David Simpson,Ming Chung Wang,Andrew Spencer,Sossana Delimpasi,Cyrille Hulin,Kazutaka Sunami,Thierry Facon,Philip Vlummens,Kwee Yong,Frank Campana,Marlène Inchauspé,Sandrine Macé,Marie-Laure Risse,Helgi van de Velde,Michel Attal +17 more
TL;DR: After 1 prior LOT, PVd significantly reduced the risk of progression or death by 53% vs Vd in pts previously treated with BORT, and second-line PVd also significantly improved ORR, regardless of prior BORT treatment, and led to deeper responses against Vd.
Journal ArticleDOI
Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma
Lilly Wong,Manisha Lamba,María Dolores Jiménez Nuñez,Daniel Bauer,Paul G. Richardson,Nizar J. Bahlis,Annette Juul Vangsted,Karthik Ramasamy,Suzanne Trudel,Joaquin Martinez-Lopez,Maria-Victoria Mateos,Paula Rodriguez-Otero,Sagar Lonial,Rakesh Popat,Albert Oriol,Chatchada Karanes,Robert Z. Orlowski,Jesus G. Berdeja,Michael Pourdehnad,Daniel W. Pierce +19 more
TL;DR: Focusing on the immunomodulatory effects, dynamic and dose- and schedule-dependent changes were demonstrated in immune cell subtypes, and CC-92480 induced rapid and sustained decreases in sFLC and sBCMA in Cycle 1 at the RP2D.
Journal ArticleDOI
Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
Paul G. Richardson,Hervé Avet-Loiseau,Antonio Palumbo,Luisa Viterbo,Arnon Nagler,Peter Ganly,Dina Ben Yehuda,Jesús F. San Miguel,S. Vincent Rajkumar,Ludek Pour,Christian Langer,Nizar J. Bahlis,Andrzej Pluta,Tamás Masszi,Deborah Berg,Jianchang Lin,Helgi van de Velde,Dixie-Lee Esseltine,Alessandra Di Bacco,Philippe Moreau +19 more
TL;DR: PFS was improved with IRd vs placebo-Rd in high- and standard-risk pts, and median PFS withIRd was similar to that in all pts and in sta...
Journal ArticleDOI
An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
TL;DR: The results confirm the superiority of MP plus bortezomib combination over MP therapy in treatment-naive patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Journal ArticleDOI
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Emil Frei,Gulshan Ara,Beverly A. Teicher,Craig A. Bunnell,Paul G. Richardson,Catherine Wheeler,Kenneth D. Tew,Anthony D. Elias +7 more
TL;DR: The sequence of alkylating agent treatment may substantially influence response and Mechanistic studies indicate significant changes in glutathione S1 transferase, a known mechanism for broadly based resistance to AAs.